Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

Status Recruiting

Clinical Trial Summary

This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD)

Clinical Trial Description

This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Up to 13 subjects will be treated with 80 mg each day for 4 weeks. The study will also evaluate effects of seliciclib on quality of life and clinical signs and symptoms of Cushing disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03774446
Study type	Interventional
Source	Cedars-Sinai Medical Center
Contact	Vivian Hwe
Phone	424-315-4489
Email	vivian.hwe@cshs.org
Status	Recruiting
Phase	Phase 2
Start date	November 2, 2018
Completion date	August 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02350153` - Cushing´s Disease Epidemiology in Sweden
Not yet recruiting	`NCT03297892` - Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015	N/A
Recruiting	`NCT05804669` - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome	Phase 1/Phase 2
Recruiting	`NCT03364803` - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Completed	`NCT03080181` - Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment	Phase 4
Recruiting	`NCT03831958` - Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Completed	`NCT01331239` - Safety and Efficacy of LCI699 in Cushing's Disease Patients	Phase 2
Completed	`NCT04201444` - Hair Cortisol and Cushing's Disease	N/A
Completed	`NCT02233335` - The Factors Associated With the Recurrence in Patients With Cushing Disease	N/A
Recruiting	`NCT04374721` - Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders	N/A
Recruiting	`NCT03974789` - Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
Completed	`NCT03621280` - Open-label Treatment in Cushing's Syndrome	Phase 3
Not yet recruiting	`NCT05971758` - Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease	Phase 2
Recruiting	`NCT04486859` - Postoperative Thrombosis Prevention in Patients With CD	N/A
Completed	`NCT00171951` - Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease	Phase 2
Recruiting	`NCT00001595` - An Investigation of Pituitary Tumors and Related Hypothalmic Disorders